Hypoxia-altitude Testing to Predict Altitude Related Adverse Health Effects in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

September 1, 2021

Study Completion Date

May 31, 2022

Conditions
Hypoxia Altitude Simulation TestHigh Altitude
Interventions
OTHER

hypoxia altitude simulation test (HAST) at 760m

Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).

PROCEDURE

High Altitude (3100m)

High Altitude (3100m) exposure for 2 days

Trial Locations (1)

720040

National Center of Cardiology and Internal Medicine, Bishkek

All Listed Sponsors
collaborator

National Center of Cardiology and Internal Medicine, Kyrgyz Republic

UNKNOWN

lead

University of Zurich

OTHER